000302010 001__ 302010
000302010 005__ 20250614115238.0
000302010 0247_ $$2doi$$a10.1186/s40644-025-00886-w
000302010 0247_ $$2pmid$$apmid:40506754
000302010 0247_ $$2ISSN$$a1470-7330
000302010 0247_ $$2ISSN$$a1740-5025
000302010 037__ $$aDKFZ-2025-01208
000302010 041__ $$aEnglish
000302010 082__ $$a610
000302010 1001_ $$00009-0007-0273-2183$$aWessendorf, Joel$$b0
000302010 245__ $$aImage analysis: 68Ga-FAPI-46 PET derived texture parameters improve the differentiation of malignant and benign pulmonary lesions.
000302010 260__ $$aLondon$$bBioMed Central$$c2025
000302010 3367_ $$2DRIVER$$aarticle
000302010 3367_ $$2DataCite$$aOutput Types/Journal article
000302010 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1749821084_3516
000302010 3367_ $$2BibTeX$$aARTICLE
000302010 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000302010 3367_ $$00$$2EndNote$$aJournal Article
000302010 520__ $$aPulmonary lesions inconclusive in 18F-FDG PET/CT are a known clinical problem. Both texture analysis and 68Ga-FAPI-46 have shown potential in thoracic oncological problems but their combination has not been assessed yet. This initial analysis aims to evaluate the utility of 68Ga-FAPI-46 PET texture parameters to differentiate between lung cancer and benign pulmonary lesions inconclusive in 18F-FDG PET/CT.20 histologically confirmed pulmonary lesions (13 lung cancer, 7 benign) in 19 patients were evaluated. All patients underwent an inconclusive 18F-FDG PET/CT before 68Ga-FAPI-46 PET/CT. 64 texture parameters and conventional parameters (SUVs, TBRs) were analyzed. Texture parameters with significant (P < 0.05) differences between lung cancer and benign lesions were detected by the Mann-Whitney U test. Boxplots and a scatter plot matrix were created. Principal component analyses and Spearman correlations were performed. Receiver operating characteristics curves with area under the curve (AUC) values were created for univariable and bivariable logistic regression.The texture parameters HIST Maximum grey level (AUC = 0.901), HIST Mean (AUC = 0.802), HIST Mode (AUC = 0.835), HIST Range (AUC = 0.901) and GLCM Information correlation 1 (AUC = 0.824) showed significant differences between lung cancer and benign pulmonary lesions. AUC values of conventional parameters (SUVmax, SUVmean, TBR(SUVmax), TBR(SUVmean)) were 0.791, 0.868, 0.802 and 0.857, respectively. Maximum AUC values of bivariable logistic regression were 0.967 and 0.978 for two texture parameters and the combination of conventional and texture parameters, respectively. Correlations between texture parameter pairs were mainly moderate (0.4≤ρ≤0.59). 2/5 texture parameters (HIST Mean, HIST Mode) displayed no very strong correlations (0.8≤ρ≤1.00) to any conventional parameters or lesion volume.68Ga-FAPI-46 PET texture parameters show great potential to differentiate between lung cancer and benign pulmonary lesions inconclusive in 18F-FDG/PET. Spearman correlations indicate additional information value of texture parameters.
000302010 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000302010 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000302010 650_7 $$2Other$$aImage analysis
000302010 650_7 $$2Other$$aLung cancer
000302010 650_7 $$2Other$$aPulmonary lesion
000302010 650_7 $$2Other$$aTexture analysis
000302010 650_7 $$2NLM Chemicals$$aGallium Radioisotopes
000302010 650_7 $$00Z5B2CJX4D$$2NLM Chemicals$$aFluorodeoxyglucose F18
000302010 650_7 $$2NLM Chemicals$$aRadiopharmaceuticals
000302010 650_2 $$2MeSH$$aHumans
000302010 650_2 $$2MeSH$$aLung Neoplasms: diagnostic imaging
000302010 650_2 $$2MeSH$$aLung Neoplasms: pathology
000302010 650_2 $$2MeSH$$aFemale
000302010 650_2 $$2MeSH$$aMale
000302010 650_2 $$2MeSH$$aMiddle Aged
000302010 650_2 $$2MeSH$$aAged
000302010 650_2 $$2MeSH$$aPositron Emission Tomography Computed Tomography: methods
000302010 650_2 $$2MeSH$$aDiagnosis, Differential
000302010 650_2 $$2MeSH$$aGallium Radioisotopes
000302010 650_2 $$2MeSH$$aFluorodeoxyglucose F18
000302010 650_2 $$2MeSH$$aRadiopharmaceuticals
000302010 650_2 $$2MeSH$$aAged, 80 and over
000302010 650_2 $$2MeSH$$aAdult
000302010 7001_ $$aSpektor, Anna-Maria$$b1
000302010 7001_ $$aAboulmaouahib, Brahim$$b2
000302010 7001_ $$aDaum, Johanna$$b3
000302010 7001_ $$aGlatting, Frederik M$$b4
000302010 7001_ $$aSchlamp, Kai$$b5
000302010 7001_ $$aGrott, Matthias$$b6
000302010 7001_ $$aEichhorn, Florian$$b7
000302010 7001_ $$aHeußel, Claus Peter$$b8
000302010 7001_ $$aKauczor, Hans Ulrich$$b9
000302010 7001_ $$aKreuter, Michael$$b10
000302010 7001_ $$aSchreckenberger, Mathias$$b11
000302010 7001_ $$aWinter, Hauke$$b12
000302010 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b13$$udkfz
000302010 7001_ $$aRöhrich, Manuel$$b14
000302010 773__ $$0PERI:(DE-600)2104862-9$$a10.1186/s40644-025-00886-w$$gVol. 25, no. 1, p. 73$$n1$$p73$$tCancer imaging$$v25$$x1470-7330$$y2025
000302010 909CO $$ooai:inrepo02.dkfz.de:302010$$pVDB
000302010 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000302010 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000302010 9141_ $$y2025
000302010 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-02
000302010 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
000302010 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:36:04Z
000302010 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:36:04Z
000302010 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2024-04-10T15:36:04Z
000302010 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-02
000302010 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-02
000302010 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-02
000302010 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-02
000302010 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-02
000302010 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-02
000302010 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-02
000302010 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000302010 980__ $$ajournal
000302010 980__ $$aVDB
000302010 980__ $$aI:(DE-He78)E060-20160331
000302010 980__ $$aUNRESTRICTED